03 Aug

Elanco’s IPO Would Free Eli Lilly to Focus on Pharmaceuticals

Elanco, the animal health business of Eli Lilly, has filed for an IPO, setting in motion the process of splitting from its parent company of more than 60 years.

Greenfield, IN-based Elanco set a preliminary $100 million target in the IPO filing, a figure used to calculate the registration fee. IPO research firm Renaissance Capital estimates that Elanco’s IPO-if it happens-could raise as much as $2.5 billion. Elanco has yet to determine how many shares it will sell and at what price. It has applied for a New York Stock Exchange listing under the stock symbol “ELAN.”

The Elanco IPO plans… Read more »

UNDERWRITERS AND PARTNERS

          

          

            

Leave a Reply